{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=25", "query": { "condition": "Adenocarcinoma Lung", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 911, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:15:25.831Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04282044", "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Colorectal Cancer", "Hepatocellular Carcinoma", "Osteosarcoma", "Epithelial Ovarian Cancer", "Gastric Cancer", "Non-small Cell Lung Cancer", "Malignant Melanoma" ], "interventions": [ { "name": "CRX100 suspension for infusion", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "COMBINATION_PRODUCT" }, { "name": "Cyclophosphamide", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "BioEclipse Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-01-08", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • La Jolla, California • Stanford, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04282044" }, { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Invasive Breast Lobular Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 138, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT00496860", "title": "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Progressive Metastatic Malignancies" ], "interventions": [ { "name": "ALT-801", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2007-05", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 4, "location_summary": "Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496860" }, { "nct_id": "NCT02450591", "title": "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oligometastatic Lung Adenocarcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Local Therapies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-05-14", "completion_date": "2017-12-11", "has_results": true, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02450591" }, { "nct_id": "NCT04263090", "title": "Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Adenocarcinoma", "Stage IV" ], "interventions": [ { "name": "Rigosertib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-06-29", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04263090" }, { "nct_id": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Melanoma", "Colo-rectal Cancer (dMMR/MSI-H CRC)", "Hepatocellular Carcinoma", "Ulcerative Colitis", "Esophageal Cancer", "Squamous Cell Carcinoma", "Gastric/GEJ", "Cervical Cancer", "Gastro-Esophageal Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "nivolumab", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2025-11-04", "completion_date": "2030-11-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223424" }, { "nct_id": "NCT04123379", "title": "Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "BMS-813160", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 48, "start_date": "2020-03-05", "completion_date": "2028-07-13", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123379" }, { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2021-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT06564844", "title": "A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Datopotamab Deruxtecan", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "UFT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-10-15", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 37, "location_summary": "Tucson, Arizona • Duarte, California • Glendale, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564844" }, { "nct_id": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Adenocarcinoma", "Ovarian Cancer", "Peritoneal Carcinoma", "Fallopian Tube Cancer", "Mesotheliomas Pleural", "Mesothelioma Peritoneum" ], "interventions": [ { "name": "huCART-meso cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-04-06", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-15T15:15:25.831Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03054298" } ] }